AIM is a non-injectable intranasal delivery vehicle — a proprietary non-Newtonian medium engineered to deliver APIs directly to the CNS via the nasal mucosa, bypassing the blood-brain barrier entirely. Manufactured in-house at our laboratory on the UMBC campus.
The closest analogy is bacteriostatic water: a vehicle, not a drug. Supplied to licensed physicians and business partners. The physician determines compound selection and administers under their own professional license and clinical judgment.
Compliance position: AIM is classified as a non-sterile compounding medium for topical intranasal use. It is not a drug and not a prescription product. No USP-797 sterile facility is required. All therapeutic use is governed solely by the physician's professional license.
Your $500 program entry is your first order — not a fee on top of it. One 50 mL vial, 200 aqueous doses at $2.50 each, shipped directly to your practice. No compounding facility required. Physician license confirmation required on first order.
All orders ship to your licensed practice address. AIM is supplied to licensed physicians only. Full citation reference whitepaper (all 15 compound studies) and observational utilization summary available. Contact us to discuss practice volume needs.
AIM is a non-Newtonian intranasal medium. It behaves as a viscous gel at rest. retaining the API at mucosal contact. and transitions to liquid under shear, enabling precise atomization through a standard nasal atomizer.
Once delivered, APIs travel via the olfactory and trigeminal nerve pathways directly to the CNS, bypassing both first-pass metabolism and the blood-brain barrier. Published research documents improved CNS bioavailability compared to the subcutaneous route for multiple compound classes.
Real-world observational reports across 10 de-identified case summaries. spanning TBI, PTSD, post-stroke recovery, neurodegenerative disease, and inflammatory conditions. describe consistent tolerance, rapid onset, and multi-day benefit from single administrations. Full observational reference document available to qualified physician inquiries.
AIM delivery volume is 0.50 mL total (0.25 mL per nostril) for both protocols. The difference is the AIM volume used per preparation: 0.25 mL AIM combined with aqueous API for liquid preparations; 0.50 mL AIM injected directly into lyophilized vials for reconstitution. API compound selection and concentration remain exclusively with the physician. AIM contains distilled water, vitamin E, and sodium ascorbate. providing an antioxidant, naturally antimicrobial environment that extends compounded medication integrity.
AIM's classification and physician-facing supply model is structured to minimize regulatory friction while preserving full clinical discretion. Three pillars underpin the compliance position.
AIM is classified as a non-sterile compounding medium for topical intranasal application. not an injectable, not a drug. This means USP-795 governs rather than USP-797, eliminating the sterile facility requirement entirely.
AIM is supplied as a standalone delivery vehicle. the same conceptual model as bacteriostatic water. The physician independently sources their compounds and determines use under their own professional license and clinical judgment.
AIM itself is not a prescription product. It is an aqueous intranasal medium supplied directly to licensed physicians for use in their practice. There is no patient-facing prescription requirement for the vehicle itself.
The full CNS compound reference, 10 de-identified observational case summaries, and clinical workflow documentation are ready to send. Request access below and we will have them in your inbox same day.
Two reference documents are available to qualified physicians. The Compound Compatibility Whitepaper requires a brief intake. we use it to verify licensure and follow up directly. The Clinical Workflow Guide is open access.
Full compound compatibility reference for licensed physicians. Peer-reviewed citations, CNS observations, and AIM delivery context for all 15 compounds tested with AIM. API compound selection and concentration are determined exclusively by the physician.
Ten de-identified observational case summaries across TBI, PTSD, post-stroke recovery, neurodegenerative disease, autism spectrum, and inflammatory conditions. Anecdotal context for physician reference only.
| Dimension | Injectable (standard) | AIM Intranasal |
|---|---|---|
| Sterility requirement | USP-797 sterile facility required | Non-sterile — no USP-797 required |
| Administration | Subcutaneous injection — needle, sharps disposal, patient training | Intranasal atomizer — no needle, no sharps |
| CNS delivery | Indirect via bloodstream only | Direct via olfactory and trigeminal nerve pathways |
| Bioavailability | Baseline systemic exposure | Substantially higher CNS bioavailability — published research |
| Patient experience | Needle anxiety, injection site reactions, sharps handling | Non-invasive nasal spray — high patient acceptance |
| Physician control | Limited by compounding facility formulary and capacity | Full — physician determines compound and concentration |
| Regulatory classification | Sterile injectable compound | Non-sterile topical — simplified compliance |
| First-pass metabolism | Subject to hepatic first-pass (oral) or systemic distribution (SQ) | Bypassed via mucosal/CNS pathway |
The following compounds have been tested with AIM delivery. Published peer-reviewed research exists for all 15. Full citation reference document available to qualified physician inquiries. Compound selection and use remain entirely under physician license.